USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

US health regulator issues warning letter to Intas Pharmaceuticals CEO and MD Nimish Chudgar for manufacturing lapses and violation of CGMP regulations at the Matoda-Sanand facility in Ahmedabad. The USFDA found various manufacturing lapses and inadequate oversight in the company's Quality Assurance and production departments. Specifically, the investigation revealed manipulation of defect counts on visual inspection records to avoid rejection limits. The company also failed to thoroughly investigate discrepancies and establish written procedures for production controls and prevention of microbiological contamination.

from Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News https://ift.tt/6jLQBWd
>

Comments

Popular posts from this blog

BTS members Jin and Jungkook unveil their postcard messages to ARMY as they gear up for ‘BE’ release 

Salman Khan reveals the three villains of Radhe-Your Most Wanted Bhai; says they made the film look stronger and bigger

Dia Mirza admits Rehnaa Hai Terre Dil Mein had sexism in it